Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 6, 2015
Pharmacy Choice - Pharmacy News - March 6, 2015

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
3/6/15 - United States : Elepsia XR Levetiracetam extended-release tablets gets nod from FDA [TendersInfo (India)]
New Drug Application for Elepsia XR has received approval from the U.S. Food and Drug Administration. Anil Raghavan, Chief Executive Officer of SPARC adds, Levetiracetam is a very successful and highly effective antiepileptic drug but more than 80% of epilepsy patients require Levetiracetam in does in range of 1000 mg to 3000 mg resulting in a sign
3/6/15 - United States : FDA expands approved use of Opdivo to treat lung cancer [TendersInfo (India)]
The U.S. Food and Drug Administration today expanded the approved use of Opdivo to treat patients with advanced squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy. Lung cancer is the leading cause of cancer death in the United States, with an estimated 224,210 new diagnoses and 159,260 deaths in 2014. The m
3/5/15 - CorMatrix Gets U.S. FDA Approval for Tricuspid Heart Valve Study [Health & Beauty Close - Up]
CorMatrix Cardiovascular reported FDA approval of an Investigational Device Exemption for an Early Feasibility Study of its CorMatrix ECM Tricuspid Heart Valve. Andrew Green, Executive Vice President of Operations, commented that, "The approval of the CorMatrix ECM Tricuspid Valve early feasibility study is a major milestone for CorMatrix and...
3/5/15 - FDA Approves Landmark Drug for Lung Cancer Patients
Today, the Bonnie J. Addario Lung Cancer Foundation applauds the U.S. Food and Drug Administrationâ?? s approval of the Bristol-Meyers Squibbâ?? s Opdivo immunotherapy drug for the treatment of lung cancer, the leading cause of cancer death in the U.S. â??Itâ?? s about time we revolutionize our approach to lung cancer treatment,â?? said Bonnie J. A
3/5/15 - Swiss Stocks Join European Rally
BRUSSELS- Swiss stocks followed other European markets higher Thursday, although strength was less pronounced in Zürich than elsewhere. Traders responded favorably to the European Central Bank's details regarding bond buying that is set to begin Monday. Lonza was up 5.4 percent after US company Bristol-Myers Squibb received FDA approval for the dr
3/4/15 - Allergan Secures FDA Approval of NATRELLE INSPIRA Round Gel-Filled Breast Implants [Health & Beauty Close - Up]
"The FDA approval of NATRELLE INSPIRA round gel-filled implants exemplifies our commitment to scientific innovation and to meeting the dynamic needs of plastic surgeons and their patients," said Scott Whitcup, M.D., Executive Vice President, Research and Development, Chief Scientific Officer, Allergan. "In the past two years, Allergan has received

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Lupus: What You Need to Know
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415